Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
Sherif M Hamdy,1 Maged Abdel-Naseer,1 Hatem S Shehata,1 Amr Hassan,1 Alaa Elmazny,1 Nevin M Shalaby,1 Noha T Abokrysha,1 Nirmeen A Kishk,1 Mona AF Nada,1 Sandra M Ahmed,1 Mohamed I Hegazy,1 Doaa Mekkawy,1 Husam S Mourad,1 Ahmed Abdelalim,1 Thomas Berger2 1Neurology Department, Faculty of Medicine, C...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fcb20240e51846c3ae34c7de93845152 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fcb20240e51846c3ae34c7de93845152 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fcb20240e51846c3ae34c7de938451522021-12-02T11:00:41ZManaging Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach1178-203Xhttps://doaj.org/article/fcb20240e51846c3ae34c7de938451522020-07-01T00:00:00Zhttps://www.dovepress.com/managing-disease-modifying-therapies-and-breakthrough-activity-in-mult-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XSherif M Hamdy,1 Maged Abdel-Naseer,1 Hatem S Shehata,1 Amr Hassan,1 Alaa Elmazny,1 Nevin M Shalaby,1 Noha T Abokrysha,1 Nirmeen A Kishk,1 Mona AF Nada,1 Sandra M Ahmed,1 Mohamed I Hegazy,1 Doaa Mekkawy,1 Husam S Mourad,1 Ahmed Abdelalim,1 Thomas Berger2 1Neurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Neurology Department, Medical University of Vienna, Vienna, AustriaCorrespondence: Amr HassanKasr Al Ainy Faculty of Medicine, Cairo University, P.O.11553, Cairo, EgyptTel +201006060809Email amrhasanneuro@kasralainy.edu.egAbstract: The emergence of the novel coronavirus disease 2019 (COVID-19) pandemic has become a major public health challenge of global concern since December 2019, when the virus was recognized in Wuhan, the capital city of Hubei province in China and epicenter of the COVID-19 epidemic. Given the novelty of COVID-19 and the lack of specific anti-virus therapies, the current management is essentially supportive. There is an absence of consensus on guidelines or treatment strategies for complex disorders such as multiple sclerosis (MS), in which the risk of infections is higher than in the general population. This is due to the overall impairment of the immune system typical of autoimmune diseases, in addition to accumulation of disabilities, and the iatrogenic effect generated by corticosteroids and the recommended disease-modifying therapies (DMTs). DMTs have different modes of action, but all modulate and interfere with the patient’s immune response, thereby raising concerns about adverse effects, such as an increased susceptibility to infections. In this review, we analyze the evidence for use of DMTs during the current critical period and ratify an algorithmic approach for management to optimize care between keeping DMTs, with their infection hazards, or coming off them, with the risk of disease activation. We also provide an algorithmic approach to the management of breakthrough activity during the COVID-19 pandemic.Keywords: COVID-19, multiple sclerosis, disease-modifying therapiesHamdy SMAbdel-Naseer MShehata HSHassan AElmazny AShalaby NMAbokrysha NTKishk NANada MAFAhmed SMHegazy MIMekkawy DMourad HSAbdelalim ABerger TDove Medical Pressarticlecovid-19multiple sclerosisdisease-modifying therapiesTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 651-662 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
covid-19 multiple sclerosis disease-modifying therapies Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
covid-19 multiple sclerosis disease-modifying therapies Therapeutics. Pharmacology RM1-950 Hamdy SM Abdel-Naseer M Shehata HS Hassan A Elmazny A Shalaby NM Abokrysha NT Kishk NA Nada MAF Ahmed SM Hegazy MI Mekkawy D Mourad HS Abdelalim A Berger T Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| description |
Sherif M Hamdy,1 Maged Abdel-Naseer,1 Hatem S Shehata,1 Amr Hassan,1 Alaa Elmazny,1 Nevin M Shalaby,1 Noha T Abokrysha,1 Nirmeen A Kishk,1 Mona AF Nada,1 Sandra M Ahmed,1 Mohamed I Hegazy,1 Doaa Mekkawy,1 Husam S Mourad,1 Ahmed Abdelalim,1 Thomas Berger2 1Neurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Neurology Department, Medical University of Vienna, Vienna, AustriaCorrespondence: Amr HassanKasr Al Ainy Faculty of Medicine, Cairo University, P.O.11553, Cairo, EgyptTel +201006060809Email amrhasanneuro@kasralainy.edu.egAbstract: The emergence of the novel coronavirus disease 2019 (COVID-19) pandemic has become a major public health challenge of global concern since December 2019, when the virus was recognized in Wuhan, the capital city of Hubei province in China and epicenter of the COVID-19 epidemic. Given the novelty of COVID-19 and the lack of specific anti-virus therapies, the current management is essentially supportive. There is an absence of consensus on guidelines or treatment strategies for complex disorders such as multiple sclerosis (MS), in which the risk of infections is higher than in the general population. This is due to the overall impairment of the immune system typical of autoimmune diseases, in addition to accumulation of disabilities, and the iatrogenic effect generated by corticosteroids and the recommended disease-modifying therapies (DMTs). DMTs have different modes of action, but all modulate and interfere with the patient’s immune response, thereby raising concerns about adverse effects, such as an increased susceptibility to infections. In this review, we analyze the evidence for use of DMTs during the current critical period and ratify an algorithmic approach for management to optimize care between keeping DMTs, with their infection hazards, or coming off them, with the risk of disease activation. We also provide an algorithmic approach to the management of breakthrough activity during the COVID-19 pandemic.Keywords: COVID-19, multiple sclerosis, disease-modifying therapies |
| format |
article |
| author |
Hamdy SM Abdel-Naseer M Shehata HS Hassan A Elmazny A Shalaby NM Abokrysha NT Kishk NA Nada MAF Ahmed SM Hegazy MI Mekkawy D Mourad HS Abdelalim A Berger T |
| author_facet |
Hamdy SM Abdel-Naseer M Shehata HS Hassan A Elmazny A Shalaby NM Abokrysha NT Kishk NA Nada MAF Ahmed SM Hegazy MI Mekkawy D Mourad HS Abdelalim A Berger T |
| author_sort |
Hamdy SM |
| title |
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| title_short |
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| title_full |
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| title_fullStr |
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| title_full_unstemmed |
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach |
| title_sort |
managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the covid-19 pandemic: toward an optimized approach |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/fcb20240e51846c3ae34c7de93845152 |
| work_keys_str_mv |
AT hamdysm managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT abdelnaseerm managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT shehatahs managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT hassana managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT elmaznya managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT shalabynm managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT abokryshant managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT kishkna managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT nadamaf managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT ahmedsm managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT hegazymi managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT mekkawyd managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT mouradhs managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT abdelalima managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach AT bergert managingdiseasemodifyingtherapiesandbreakthroughactivityinmultiplesclerosispatientsduringthecovid19pandemictowardanoptimizedapproach |
| _version_ |
1718396389758599168 |